Allergy Therapeutics plc provided revenue guidance for the six months ended 31 December 2022. For the period, the company expects revenue to be £39.9 million (2021: £48.7 million) representing a reduction of 18% compared to last year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.5 GBX | -1.43% |
|
+7.84% | +120.00% |
1st Jan change | Capi. | |
---|---|---|
+120.00% | 340M | |
+20.17% | 126B | |
+24.67% | 118B | |
+25.44% | 27.87B | |
-17.74% | 20.95B | |
-15.17% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- AGY Stock
- News Allergy Therapeutics plc
- Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended 31 December 2022